The extraordinary scope and magnitude of the recent financial crisis of 2007-09 required an extraordinary response by the Fed in the fulfillment of its lender-of-last-resort function.
The long timelines for drug development stem from a large number of factors, but one of the key reasons is that the FDA, largely in response to major drug problems with drugs like Rezulin and the Cox-2 inhibitors, has required larger and longer trials.